![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information)
88MB |
| Item Type: | Article |
|---|---|
| Title: | Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma |
| Creators Name: | Schick, M. and Zhang, L. and Maurer, S. and Maurer, H.C. and Isaakaidis, K. and Schneider, L. and Patra, U. and Schunck, K. and Rohleder, E. and Hofstetter, J. and Baluapuri, A. and Scherger, A.K. and Slotta-Huspenina, J. and Hettler, F. and Weber, J. and Engleitner, T. and Maresch, R. and Slawska, J. and Lewis, R. and Istvanffy, R. and Habringer, S. and Steiger, K. and Baiker, A. and Oostendorp, R.A.J. and Miething, C. and Lenhof, H.P. and Bassermann, F. and Chapuy, B. and Wirth, M. and Wolf, E. and Rad, R. and Müller, S. and Keller, U. |
| Abstract: | SUMOylation is a post-translational modification of proteins that regulates these proteins' localization, turnover or function. Aberrant SUMOylation is frequently found in cancers but its origin remains elusive. Using a genome-wide transposon mutagenesis screen in a MYC-driven B-cell lymphoma model, we here identify the SUMO isopeptidase (or deconjugase) SENP6 as a tumor suppressor that links unrestricted SUMOylation to tumor development and progression. Notably, SENP6 is recurrently deleted in human lymphomas and SENP6 deficiency results in unrestricted SUMOylation. Mechanistically, SENP6 loss triggers release of DNA repair- and genome maintenance-associated protein complexes from chromatin thereby impairing DNA repair in response to DNA damages and ultimately promoting genomic instability. In line with this hypothesis, SENP6 deficiency drives synthetic lethality to Poly-ADP-Ribose-Polymerase (PARP) inhibition. Together, our results link SENP6 loss to defective genome maintenance and reveal the potential therapeutic application of PARP inhibitors in B-cell lymphoma. |
| Keywords: | Carbon-Nitrogen Lyases, Chromatin, Cysteine Endopeptidases, DNA Damage, DNA Repair, Diffuse Large B-Cell Lymphoma, Genomic Instability, Inbred C57BL Mice, Mutation, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases, Post-Translational Protein Processing, Sumoylation, Synthetic Lethal Mutations, Transgenic Mice, Tumor Biomarkers, Xenograft Model Antitumor Assays, Animals, Mice |
| Source: | Nature Communications |
| ISSN: | 2041-1723 |
| Publisher: | Nature Publishing Group |
| Volume: | 13 |
| Number: | 1 |
| Page Range: | 281 |
| Date: | 12 January 2022 |
| Official Publication: | https://doi.org/10.1038/s41467-021-27704-8 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
